Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1Graft vs Host Disease 1

Interventions

Tacrolimus 29fludarabine phosphate 21Methotrexate 21Cyclophosphamide 21Mycophenolic Acid 18Busulfan 15Antilymphocyte Serum 14Whole-Body Irradiation 13Sirolimus 12fludarabine 11Peripheral Blood Stem Cell Transplantation 11Cyclosporine 9thymoglobulin 8Melphalan 8Hematopoietic Stem Cell Transplantation 6Granulocyte Colony-Stimulating Factor 6Filgrastim 6Rituximab 5Pentostatin 5Methylprednisolone 5Thiotepa 4Stem Cell Transplantation 4Radiotherapy 4Cyclosporins 4ruxolitinib 3Vorinostat 3Transplantation 3Flow Cytometry 3Etoposide 3merphos 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Graft vs Host Disease × tildrakizumab × Clear all
NCT04112810 2025-10-21

Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease

Medical College of Wisconsin

Phase 2 Completed
51 enrolled 19 charts
Other hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡